Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficiacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated with Complement Inhibitors	Roche	Ongoing	Crovalimab	3	BO42161	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficiacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors	Roche	Completed	Crovalimab	3	BO42162	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)	Janssen-Cilag International NV	Ongoing	Carvkti	2	68284528MMY2003	King Faisal Specialist Hospital and Research Center (Riyadh)
Minimal Effective Concentration of Lidocaine in Propofol Lidocaine Mixture for Relief of Pain on Propofol Injection	King Fahd University Hospital	Rejected	lidocaine	4	IRB-2020-3	King Fahad University Hospital (Al-Khobar)
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 3 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging. (RESTORE)	Selexipag	Completed	Selexipag	3	67896049PAH4005	King Faisal Specialist Hospital and Research Center (Riyadh)
A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in mechanically ventilated critically ill patients following traumatic injury	KAIMRC/Australian and New Zealand Intensive Care Research Centre	Ongoing	Epoetin Alfa (Recombinant Human Erythropoietine) (EPREX)	3	EPO-TRAUMA ANZIC-RC/CF001 - CT20/046/R	King Abdulaziz Medical City NG (Riyadh)
An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial	Global Blood Therapeutics (GBT)	Ongoing	Inclacumab	3	GBT2104-133	Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises	Global Blood Therapeutics (GBT)	Completed	Inclacumab	3	GBT2104-132	Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi
Nucala Effectiveness Study (NEST) in Emerging Markets	King Fahd University Hospital	Completed	Mepolizumab	3	213475	King Fahad University Hospital (Al-Khobar)
Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine use beyond 24 horse Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KASCH-NGHA	KAIMRC	Ongoing	Dexmedetomidine	3	RC20/160/R	King Abdulaziz Medical City NG (Riyadh)